Nebius Shares Drop on $4.5 Billion Convertible Notes Offering and Exchange Deals
Shares fall in premarket on dilution fears as funds target AI data centers and GPUs.
Already have an account? Sign in.
Shares fall in premarket on dilution fears as funds target AI data centers and GPUs.
The FDA approved Scholar Rock’s Isembyld, the first SMA therapy aimed at muscle wasting in patients already on nerve-targeted treatment.
The Phase III SERENA-4 trial did not meet its primary PFS endpoint in untreated advanced ER-positive, HER2-negative breast cancer, despite a numerical benefit.
Citi added a 90-day upside view on AppLovin with a $600 target, calling Q3 concerns misguided.